Why The FDA Is Encouraging Sponsors To Use Mobile Medical Professionals

The FDA has been advocating for increased diversity in clinical trials for decades but, by its own account, little progress has been made and certain groups remain woefully underrepresented in many studies.  But could we now be at a turning point where talk about increasing diversity and inclusiveness translates into action and real change occurs? All indications point to “yes”, with the FDA issuing a second set of guidelines for how study sponsors can increase racial and ethnic diversity in clinical trials. Such guidance is causing many in the trials industry to look for more opportunities to incorporate a decentralized trial option into their protocols, as DCTs can help to recruit and retain more diverse patient populations.